Back to News
Market Impact: 0.3
Viva Biotech Reports H1 2026 Results, Revenue Rises 21% On CDMO Growth
Source: Nasdaq
Corporate EarningsCompany FundamentalsCorporate Guidance & Outlook
Viva Biotech reported interim results for the six months ended June 30, 2026, with revenue up 21% YoY. Growth was driven primarily by Langhua Pharmaceutical’s CDMO business and progress in commercial manufacturing advancement. Overall tone is cautiously positive, but the article is truncated and provides limited detail on profitability and outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VBIZF0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- European bank stocks slide 8% as bond yields spark investor caution
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant